TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY

Women with cervical cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

You may be eligible to participate in this study if you:

  • Are a female at least 18 years of age
  • Stage IVB, recurrent or persistent cervical cancer
  • After at least 1 line of prior therapy
  • Adequate hematologic and organ function
  • No active infection

You may NOT participate in this study if you:

  • Have planned surgery during the study
  • Have active tuberculosis or leptomeningeal disease
  • Have known immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
  • Are pregnant or breastfeeding

Contact Information
Martina Kracikova, Study Coordinator
One Gustave L. Levy Place, Box 1170
New York, NY 10029
Phone: (212) 824-7859
Email: Martina.kracikova@MSSM.EDU